Glaukos Corp  (GKOS)
Other Ticker:  
Price: $71.3500 $0.25 0.352%
Day's High: $71.785 Week Perf: -8.97 %
Day's Low: $ 69.99 30 Day Perf: -4.73 %
Volume (M): 730 52 Wk High: $ 80.28
Volume (M$): $ 52,114 52 Wk Avg: $57.66
Open: $70.81 52 Wk Low: $40.45

 Market Capitalization (Millions $) 3,445
 Shares Outstanding (Millions) 48
 Employees 900
 Revenues (TTM) (Millions $) 297
 Net Income (TTM) (Millions $) -126
 Cash Flow (TTM) (Millions $) -11
 Capital Exp. (TTM) (Millions $) 27

Glaukos Corp
Glaukos Corporation is a medical technology company that focuses on developing and commercializing products and procedures to treat glaucoma, one of the leading causes of blindness worldwide. It was founded in 1998 and is headquartered in San Clemente, California, United States.

Glaukos Corporation offers a broad range of innovative glaucoma treatments that are designed to offer safe, long-lasting, and effective relief to patients suffering from this debilitating eye disease. The company's flagship product is the iStent, which is the world's first micro-bypass stent approved for use in patients with mild to moderate open-angle glaucoma. This tiny stent is placed into the eye during a minimally invasive procedure, through which it helps to alleviate intraocular pressure by improving the drainage of fluid from the eye.

Beyond the iStent, Glaukos offers a suite of glaucoma products that leverage the company's expertise in micro-scale devices and implantable technologies. These products include the iStent Inject, a next-generation version of the iStent that offers increased flow through two stents, as well as the iStent SA, which is designed for use in patients who are undergoing cataract surgery.

In addition to its product offerings, Glaukos has a robust research and development program that is focused on advancing the field of glaucoma treatment. This includes a pipeline of novel devices, surgical systems, and drug-delivery technologies that aim to address unmet needs in the glaucoma market.

The company's strong growth in recent years has been driven by its ability to provide compelling solutions to a significant unmet need in the ophthalmology marketplace. In 2020, Glaukos generated revenues of $196 million, a7% increase from the previous year.

Overall, Glaukos Corporation is a leading player in the ophthalmology space, with a strong track record of innovation and a commitment to improving patients' lives. As the company continues to invest in research and development, it is well-positioned to remain a key player in the glaucoma market for years to come.

   Company Address: One Glaukos Way Aliso Viejo 92656 CA
   Company Phone Number: 367-9600   Stock Exchange / Ticker: NYSE GKOS
   GKOS is expected to report next financial results on November 02, 2023.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Fonar Corporation

Fonar Corporation Faces Steep Decline in Fourth Quarter, Sinking into Negative Territory

In the recent fiscal period, Fonar Corporation, a prominent player in the Medical Equipment and Supplies sector, reported disappointing financial results. However, despite the challenges faced, there are reasons to be cautiously optimistic about the company's future performance. This article will provide an in-depth analysis of Fonar Corporation's financials and evaluate its potential for recovery.
Financial Performance
Fonar Corporation experienced a significant drop in its earnings per share (EPS) from $0.23 to -$1.16 compared to the same period last year. Meanwhile, its revenue showed moderate growth, with a 3.885% increase to $25.78 million. This growth, however, falls short of the 4.79% expected by the Medical Equipment and Supplies sector as a whole.

Precision Optics Corporation Inc

Precision Optics Corporation Inc Announces a Remarkable Financial Turnaround, Amidst Challenging Market Conditions, in Q4 2023 Financial Report

Precision Optics Corporation Inc (POCI) has experienced a slight increase in its stock value over the past week, rising by 0.66%. Additionally, its stock currently trades 6.5% above its 52-week low. These figures indicate positive performance for the company in the stock market.
Examining POCI's financial report for the fourth quarter of 2023, it is evident that the company faced a net loss per share of $-0.11. This represents a decline from the $0.08 per share profit reported in the previous year. However, despite the loss, POCI saw a 4.811% increase in revenue, reaching $5.02 million compared to the corresponding reporting period the previous year.

Heart Test Laboratories Inc

Advanced Heart Test Laboratories Inc. Witnesses Promising Revenue Similar to Previous Year's Quarter, as Efforts Focus on Q1 2024

Heart Test Laboratories Inc, a medical device manufacturing company, recently released its financial results for the first quarter of the 2024 earnings season. The figures demonstrate a significant decrease in loss per share compared to the previous year, as well as an improvement in earnings per share. Although the revenue remained unchanged, the company reported a lower net shortfall compared to the same reporting season the previous year. This article aims to provide an overview of Heart Test Laboratories Inc's Q1 2024 financial results and analyze them within the context of recent stock performance.
Financial Results:
Heart Test Laboratories Inc reported a loss per share of $-0.13 in the first quarter of 2024, a considerable improvement from the loss per share of $-0.28 in the same reporting season the previous year. Additionally, the company's earnings per share increased from $-0.16 in the previous reporting season. Despite these positive developments, the revenue for Q1 2024 remained unchanged at $0.00 million, both compared to the same reporting season a year before and sequentially.

Sensasure Technologies Inc

Company Struggles Amidst Challenging First Quarter in 2024

Date: August 1, 2023
As the financial interval closing July 31, 2023 draws to a close, Sensasure Technologies Inc, a leading technology company, has achieved a significant milestone by reaching break-even at $0.00 per share. This marks an improvement from the same reporting period a year ago when the company also reported a break-even, and from the preceding reporting period.
However, while this is an encouraging development for Sensasure Technologies Inc, it is crucial to examine the context of the financial results to gain deeper insights.

Innovage Holding Corp

Innovage Holdings Corp Suffers Loss Despite Revenue Surge in Fourth Quarter of 2023

Innovage Holding Corp, a Medical Equipment and Supplies company, recently released its financial results for the fourth quarter of 2023. Despite reporting a loss of $0.08 per share, compared to $0.09 in the previous year, the company's revenue grew moderately by 2.322% to $176.87 million.
However, this revenue surge was lower than the average growth rate of 4.80% for the Medical Equipment and Supplies sector during the same period. Analysts believe that this slower growth may be due to a decline in demand, as evidenced by the decrease in accounts receivable to $24.3 million.


Glaukos's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com